Oncology and reproductive outcomes over 16 years of malignant ovarian germ cell tumors treated by fertility sparing surgery

Table 4 Details of premature menopausal patients (n = 7)

SN	Year	Age	Stage	Histology	Chemotherapy	Cycle	Site	Primary surgery	Note
25	2017	29	IIA	Yolk sac tumor	BEP	6	Right	Right SO and omentectomy January 6, 2017	16/1/18 abdominal pain and pelvic mass size 10 cm × 15 cm, solid and cystic, movable AFP 2.2 → TAH and left SO 19/1/18 → endometrioid CA IA → carboplatin × 6 → complete response → DFS 61 mo, HRT
43	2014	16	III	Dysgerminoma	BEP	4	Bilateral	Left SO and omentectomy	Partial response during BEP, overall survival of 3 mo, death from sepsis (neutropenia)
52	2013	15	IV	Yolk sac tumor	BEP	8	Right	Right salpingo-oophorectomy with left ovarian cystectomy	PFS 15 mo → TIP × 2 cycles → PT × 1 → ifosfamide × 1 cycle → death OS 16 mo
87	2008	28	I	Dysgerminoma	BEP	3	Left	Left SO	HRT icycloprogynova lost to follow up since 2009, unknown status
108	2005	15	III	Yolk sac tumor	BEP	6	Right	Right SO	Febrile neutropenia → sepsis → death 2005 OS 9 mo
110	2005	16	IV	Yolk sac tumor	BEP × 2 → EP × 11	12	Right		Progression after EP × 11 → ifosfamide × 1 → EMA × 1 → single paclitaxel × 1 → palliative RT January 25, 2006 → VAC × 1 → Death July 4, 2007, OS 30 mo (lung fibrosis after BEP × 2)
114	2005	23	II	Dysgerminoma	BEP	6	Right	Right SO	Alive, loss after 12 mo since start treatment, no HRT

BEP: Bleomycin etoposide cisplatin; SO: Salpingo-oophorectomy; TAH: Total abdominal hysterectomy; AFP: Alpha-fetoprotein; DFS: Disease free survival; HRT: Hormonal replacement therapy; PFS: Progression free survival; TIP: Paclitaxel ifosfamide cisplatin; PT: Paclitaxel carboplatin; OS: Overall survival; EP: Etoposide cisplatin; EMA: Etoposide methotrexate + actinomycin D; palliative RT: Radiotherapy.